May. 13 at 11:39 AM
$ABEO Q1 '26 Earnings Results & Recap
• Reported GAAP EPS of -
$0.30 down -25.00% YoY
• Reported revenue of
$8.72M
• Abeona Therapeutics Inc. expects current capital resources to fund operations for at least 12 months. The company plans to file an IND for ABO-701 and commence first-in-human studies in the second half of 2027.